$MEIP
MEI Pharma, Inc.

2020 Q2 Form 10-K Financial Statement

#000119312520242169 Filed on September 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $25.50M $1.129M $1.249M
YoY Change 2158.99% 106.02% 188.45%
Cost Of Revenue $480.0K $1.100M $1.163M
YoY Change -56.36% -0.9% 25.05%
Gross Profit $25.02M $30.00K $86.00K
YoY Change 83300.0% -105.36% -117.3%
Gross Profit Margin 98.1% 2.66% 6.89%
Selling, General & Admin $4.530M $3.740M $3.630M
YoY Change 21.12% 52.03% 45.78%
% of Gross Profit 18.11% 12466.67% 4220.93%
Research & Development $7.860M $8.030M $9.071M
YoY Change -2.12% 80.04% 195.38%
% of Gross Profit 31.41% 26766.67% 10547.67%
Depreciation & Amortization $20.00K $30.00K $20.00K
YoY Change -33.33% 200.0% 100.0%
% of Gross Profit 0.08% 100.0% 23.26%
Operating Expenses $12.39M $11.78M $9.071M
YoY Change 5.18% 70.48% 195.38%
Operating Profit $12.63M -$11.75M -$12.62M
YoY Change -207.49% 57.3% 108.39%
Interest Expense -$31.11M $14.80M -$4.740M
YoY Change -310.2% -225.64% -4409.09%
% of Operating Profit -246.32%
Other Income/Expense, Net $0.00 $14.36M -$5.200M
YoY Change -100.0% -247.89%
Pretax Income -$18.48M $3.050M -$17.36M
YoY Change -705.9% -115.84% 191.76%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$18.48M $3.052M -$17.35M
YoY Change -705.37% -115.85% 191.76%
Net Earnings / Revenue -72.44% 270.33% -1389.43%
Basic Earnings Per Share -$0.17 $0.04 -$0.24
Diluted Earnings Per Share -$0.17 -$0.15 -$0.24
COMMON SHARES
Basic Shares Outstanding 106.0M 71.29M 71.20M
Diluted Shares Outstanding 71.20M

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $182.6M $74.50M $82.30M
YoY Change 145.1% -27.46% 127.35%
Cash & Equivalents $12.33M $9.590M $7.426M
Short-Term Investments $170.3M $64.90M $74.90M
Other Short-Term Assets $5.000M $2.400M $3.200M
YoY Change 108.33% 50.0% 255.56%
Inventory
Prepaid Expenses
Receivables $600.0K
Other Receivables $20.40M
Total Short-Term Assets $208.6M $82.20M $85.44M
YoY Change 153.83% -21.21% 130.58%
LONG-TERM ASSETS
Property, Plant & Equipment $1.084M $204.0K $213.0K
YoY Change 431.37% 537.5% 491.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.084M $465.0K $483.0K
YoY Change 133.12% 41.77% 41.64%
TOTAL ASSETS
Total Short-Term Assets $208.6M $82.20M $85.44M
Total Long-Term Assets $1.084M $465.0K $483.0K
Total Assets $209.7M $82.66M $85.93M
YoY Change 153.71% -21.02% 129.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.437M $4.787M $1.969M
YoY Change -49.09% 31.4% 56.39%
Accrued Expenses $6.090M $4.559M $5.685M
YoY Change 33.58% 31.99% 138.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.30M $14.30M $11.85M
YoY Change 62.95% 81.37% 164.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.2M $20.40M $36.20M
YoY Change 430.39% -55.94%
Total Long-Term Liabilities $108.2M $20.40M $36.20M
YoY Change 430.39% -55.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.30M $14.30M $11.85M
Total Long-Term Liabilities $108.2M $20.40M $36.20M
Total Liabilities $131.5M $34.73M $48.04M
YoY Change 278.63% -35.91% 967.64%
SHAREHOLDERS EQUITY
Retained Earnings -$277.2M -$231.2M -$234.3M
YoY Change 19.9% 7.84% 20.05%
Common Stock $355.5M $279.1M $272.2M
YoY Change 27.33% 5.4% 19.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.06M $47.93M $37.88M
YoY Change
Total Liabilities & Shareholders Equity $209.7M $82.66M $85.93M
YoY Change 153.71% -21.02% 129.77%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$18.48M $3.052M -$17.35M
YoY Change -705.37% -115.85% 191.76%
Depreciation, Depletion And Amortization $20.00K $30.00K $20.00K
YoY Change -33.33% 200.0% 100.0%
Cash From Operating Activities $69.11M -$8.060M -$11.34M
YoY Change -957.44% 114.93% 81.73%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$10.00K -$40.00K
YoY Change 900.0%
Acquisitions
YoY Change
Other Investing Activities -$84.94M $9.970M $9.800M
YoY Change -951.96% -116.78% 92.53%
Cash From Investing Activities -$85.04M $9.960M $9.760M
YoY Change -953.82% -116.76% 91.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.83M 280.0K 250.0K
YoY Change 7339.29% -99.6%
NET CHANGE
Cash From Operating Activities 69.11M -8.060M -11.34M
Cash From Investing Activities -85.04M 9.960M 9.760M
Cash From Financing Activities 20.83M 280.0K 250.0K
Net Change In Cash 4.900M 2.180M -1.330M
YoY Change 124.77% -69.34% 15.65%
FREE CASH FLOW
Cash From Operating Activities $69.11M -$8.060M -$11.34M
Capital Expenditures -$100.0K -$10.00K -$40.00K
Free Cash Flow $69.21M -$8.050M -$11.30M
YoY Change -959.75% 114.67% 81.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261000
CY2019Q2 us-gaap Assets
Assets
82663000
CY2020Q2 us-gaap Assets
Assets
209728000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
204000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2019Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
74489000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
182630000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2435000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5594000
CY2019Q2 us-gaap Short Term Investments
ShortTermInvestments
64899000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
170299000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4787000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2437000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4559000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6090000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
82198000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
208644000
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4955000
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14777000
CY2019Q2 us-gaap Liabilities
Liabilities
34733000
CY2020Q2 us-gaap Liabilities
Liabilities
131510000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82663000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209728000
CY2019Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
17613000
CY2020Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
40483000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
279148000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355452000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14301000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23304000
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231218000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277234000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
47930000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4263000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3383000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2671000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32300000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17038000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34065000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14597000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9787000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16717000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
51160000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
30208000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
53453000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16819000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40068000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46016000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-54613000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40068000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-46016000
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
27632000
CY2018 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-9705000
CY2019 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1795000
CY2018 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
591000
CY2020 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1395000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2019 us-gaap Revenues
Revenues
4915000
CY2018 us-gaap Revenues
Revenues
1622000
CY2020 us-gaap Revenues
Revenues
28913000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-46245000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-28586000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-24540000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71139000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41431000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91080000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72385000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41431000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91080000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
109000
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
27632000
CY2018 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-9705000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
849000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-172000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1144000
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3058000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1105000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
669000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-208000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3159000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2350000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1470000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
217000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
64655000
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
114233000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
372000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
329000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1118000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
324000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1386000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70213000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
267000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
894000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74777000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
89190000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
69906000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24318000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
190279000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
84879000
CY2019Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2819000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9590000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3719000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4851000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2741000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44327000
CY2019 us-gaap Profit Loss
ProfitLoss
-16819000
CY2018 us-gaap Profit Loss
ProfitLoss
-40068000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29423000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21035000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106294000
CY2020 us-gaap Profit Loss
ProfitLoss
-46016000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34258000
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
82500000
CY2020 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
14800000
CY2020 meip Additional Recognition Of Deferred Revenue
AdditionalRecognitionOfDeferredRevenue
67700000
CY2019 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
1700000
CY2020 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
6600000
CY2020Q2 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
400000
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
36600000
CY2020 meip Exercise Of Warrants For Common Stock
ExerciseOfWarrantsForCommonStock
440043
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
17600000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3217000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.937
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.78
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6562000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.40
CY2020Q2 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6801000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15290655
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8330387
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8356961
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3733333
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.50
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
153679
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.77
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
125749
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.45
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
557890
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.89
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11252976
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5475069
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.66
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4700000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.741
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.825
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
5274000
CY2018 meip Warrant Finance Cost
WarrantFinanceCost
2367000
CY2018 meip Warrant Finance Cost
WarrantFinanceCost
2367000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
220000
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
70151000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
69231000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
71139000
CY2018 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
41064000
CY2020 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
91080000
CY2018 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
367000
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1246000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16151000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9474000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
34000
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
298000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1146000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27092000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
94000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
62000
CY2020Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
2343000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1973000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3410000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
316000
CY2019 us-gaap Depreciation
Depreciation
45000
CY2018 us-gaap Depreciation
Depreciation
18000
CY2020 us-gaap Depreciation
Depreciation
75000
CY2019Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
2014000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
226000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
256000
CY2020Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
226100000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5400000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3400000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2400000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4376928
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.51
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.50
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
76563
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
2.86
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2255791
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.26
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5777907
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.96
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16819000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-40068000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-46016000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16819000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-40068000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46016000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3532000
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11019000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.28
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-9663000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-86000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
5370000
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.13
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-9000
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
478000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.03
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
537000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
638000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9082000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.54
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-14914000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.37
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4230000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.09
CY2019 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
0.00
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
15870000
CY2018 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
-0.40
CY2020 meip Effective Income Tax Rate Reconciliation Revaluation Of Deferred Taxes
EffectiveIncomeTaxRateReconciliationRevaluationOfDeferredTaxes
0.00
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-138000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
837000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18510000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-46016000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18476000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4329000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-20217000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2994000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2214000
CY2019Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
15328000
CY2020Q2 meip Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
18832000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3081000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3834000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
85000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
709000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
41000
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
20000
CY2019Q2 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
22000
CY2020Q2 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38702000
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42934000
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38702000
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42934000
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
4200000
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
19100000
CY2019Q2 us-gaap Revenues
Revenues
1129000
CY2019Q1 us-gaap Revenues
Revenues
1249000
CY2018Q4 us-gaap Revenues
Revenues
2049000
CY2018Q3 us-gaap Revenues
Revenues
488000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
3052000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17354000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
12025000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14542000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-16819000
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2020Q2 us-gaap Revenues
Revenues
25504000
CY2020Q1 us-gaap Revenues
Revenues
1244000
CY2019Q4 us-gaap Revenues
Revenues
1008000
CY2019Q3 us-gaap Revenues
Revenues
1157000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2019Q2 meip Non Cash Proceeds From Sale Of Common Stock Receivable
NonCashProceedsFromSaleOfCommonStockReceivable
5224000
CY2019Q2 meip Non Cash Proceeds From Stock Option Exercised Receivable
NonCashProceedsFromStockOptionExercisedReceivable
50000
CY2019Q2 meip Change In Fair Value Of Warrants Exercised
ChangeInFairValueOfWarrantsExercised
1068000
CY2020Q2 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
182600000
CY2019 meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-37794000
CY2019 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
-5803000
CY2018 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
3320000
CY2019 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
0.35
CY2018 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
-0.08
CY2020 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Percentage
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityPercentage
-0.10
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 meip Effective Income Tax Rate Reconciliation Tax Expensebenefit Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationTaxExpensebenefitWarrantLiabilityAmount
4803000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2000
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
67723000
CY2020 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00
CY2020 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-267000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
329000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111514000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73545000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111514000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73545000
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-22870000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
50838000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-40068000
CY2018 meip Stock Issued During The Period Value Private Placement
StockIssuedDuringThePeriodValuePrivatePlacement
35910000
CY2018 meip Stock Issued During The Period Value Milestone Payment
StockIssuedDuringThePeriodValueMilestonePayment
500000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3217000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50459000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5444000
CY2019 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
2186000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-324000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6562000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69231000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
272000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6801000
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-22870000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
272000
CY2020 meip Proceeds From Previously Issued Common Stock
ProceedsFromPreviouslyIssuedCommonStock
5274000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2019 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2018Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
82000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2605000
CY2019 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-82000
CY2020Q2 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
2605000
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
686000
CY2018Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
312000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-82000
CY2019 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
374000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
604000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7774000
CY2018Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
788000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
74726000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6986000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
82500000
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
17325000
CY2019Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1635000
CY2020 dei Security12b Title
Security12bTitle
Common Stock
CY2020 dei Trading Symbol
TradingSymbol
MEIP
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112522001
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
CY2019Q2 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
CY2020Q2 meip Profits And Costs Sharing Ratio
ProfitsAndCostsSharingRatio
0.5
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2020Q2 meip Receivable For Foreign Tax Withholding
ReceivableForForeignTaxWithholding
20420000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
227000
CY2020 meip Increase Or Decrease In Receivable For Foreign Tax Withholding
IncreaseOrDecreaseInReceivableForForeignTaxWithholding
-20420000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.80
CY2020 meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
CY2020Q2 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
178900000
CY2020Q2 meip Remaining Available Under Atm Sales Agreement
RemainingAvailableUnderAtmSalesAgreement
3200000
CY2019Q4 dei Entity Public Float
EntityPublicFloat
261500000
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Other Information
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleOtherInformation
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
CY2020 meip Number Of Candidate In An Ongoing Global Registration Trial
NumberOfCandidateInAnOngoingGlobalRegistrationTrial
1
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0

Files In Submission

Name View Source Status
0001193125-20-242169-index-headers.html Edgar Link pending
0001193125-20-242169-index.html Edgar Link pending
0001193125-20-242169.txt Edgar Link pending
0001193125-20-242169-xbrl.zip Edgar Link pending
d58841d10k.htm Edgar Link pending
d58841dex1018.htm Edgar Link pending
d58841dex231.htm Edgar Link pending
d58841dex311.htm Edgar Link pending
d58841dex312.htm Edgar Link pending
d58841dex321.htm Edgar Link pending
d58841dex43.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g58841stamp167logo1.jpg Edgar Link pending
g58841stamp167logo2.jpg Edgar Link pending
g58841stamp3.jpg Edgar Link pending
g58841stamp5.jpg Edgar Link pending
g58841stamp6.jpg Edgar Link pending
meip-20200630.xml Edgar Link completed
meip-20200630.xsd Edgar Link pending
meip-20200630_cal.xml Edgar Link unprocessable
meip-20200630_def.xml Edgar Link unprocessable
meip-20200630_lab.xml Edgar Link unprocessable
meip-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending